Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
87 results about "Histone Demethylases" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Enzymes that catalyse the removal of methyl groups from LYSINE or ARGININE residues found on HISTONES. Many histone demethylases generally function through an oxidoreductive mechanism.
Inhibitors of histone demethylases
Compounds of the formIn which Q is selected from —CH═NR12, —W, —CH2NHR13, —CH═O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
Owner:GILEAD SCI INC
Inhibitors of histone demethylases
The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form
Owner:GILEAD SCI INC
Tranylcypromine derivatives as inhibitors of histone demethylases lsd1 and/or lsd2
ActiveUS20130035377A1Avoid rapid distributionImprove stabilityBiocideCarbamic acid derivatives preparationDiseaseHistone demethylation
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and / or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized by deregulation of gene transcription, cell differentiation and proliferation, e.g. tumors, viral infections, are herein described. These compounds belong to the structural formula (I) wherein A and R3 are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to compositions containing them and to therapeutic use thereof.
Owner:FOND IEO 50 +2
Novel compound, preparing method thereof, and use thereof as inhibitors of histone demethylase
ActiveUS20150133564A1Inhibitory activityBiocideOrganic chemistryHistone demethylationStereochemistry
Provided are a novel compound, preparing method thereof, and use thereof as inhibitor of histone demethylase. The compound represented by Chemical Formula 1 has activity which inhibits histone demethylase and thus is capable of specifically and effectively inhibit activity of histone demethylase.
Owner:SEOUL NAT UNIV R&DB FOUND +2
Method of preventing or treating viral infection
InactiveUS20130123344A1Avoid virus infectionBiocideOrganic chemistryChemical compoundPharmaceutical drug
Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.
Owner:UNITED STATES OF AMERICA
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Therapeutic compounds and uses thereof
The present invention relates to compounds formula (I):and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.
Owner:GENENTECH INC +1
Small-molecular compound combination for differentiated cell reprogramming, reagent kit and application of small-molecular compound combination
ActiveCN108060120AGood multiple germ layer multilineage differentiation potentialStable passageSkeletal/connective tissue cellsCell culture active agentsBeta-cateninReprogramming
The invention discloses a small-molecular compound combination for differentiated cell reprogramming, and a reagent kit and an application of the small-molecular compound combination. The small-molecular compound combination includes the following components: a TGF-beta inhibitor, a WNT / beta-catenin agonist, a cAMP agonist and a PKC inhibitor; furthermore, the small-molecular compound combinationalso includes at least one of an RAR agonist, a DNMT inhibitor, an HMT inhibitor, a histone demethylase inhibitor, ascorbic acid, a JNK inhibitor, an ROCK inhibitor and a lysine deacetylase inhibitor.Differentiated cells can be reprogrammed into mesenchymal stem cells by phased induction with the small-molecular compound combination, all steps can be subjected to precise quality control, and standardization operation and large-scale production are convenient. The method provided by the invention has wide donor sources, a patient himself can be used as a donor, and the mesenchymal stem cells needed for basic research, clinical treatment or tissue engineering production can be obtained in relatively short time.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD
Histone demethylase gene OsJMJ706 of rice, encoding protein thereof and applications
The invention belongs to the technical field of plant gene engineering, and more particularly relates to a paddy rice histone demethyl methylase gene, coded protein and the application thereof. The invention provides a new paddy rice histone demethyl methylase gene OsJMJ706, due to inactivation, heteroplasia of rice flowerthe, heteroplasia or deficit of internal and external glumes, as well as lessening of seeds can be caused on the gene, and by being detected by the method of western blot, the gene is proved to have enzyme activity for removing histone H3K9me3 and H3K9me2 locus methylate. The invention provides nucleic acid sequence and protein sequence of the gene as well as the application thereof.
Owner:HUAZHONG AGRI UNIV
Histone Demethylation Mediated By The Nuclear Amine Oxidase Homolog LSD1
LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
In one aspect, the invention relates to substituted (E)-N'-(1- phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:UNIV OF UTAH RES FOUND
Histone demethylase inhibitors and methods for using the same
The present invention provides compounds, or derivatives or prodrugs thereof, that comprise a methyllysine mimic, and an α-ketoglutarate mimic that are attached through a linker and methods for using and producing the same. In some embodiments, compounds of the invention are of the formula: M-L-K, or a derivative or a prodrug thereof, wherein M is a methyllysine mimic, L is a linker, and K is an α-ketoglutarate mimic.
Owner:UNIV OF COLORADO THE REGENTS OF
Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia
InactiveCN111888474AOrganic active ingredientsHybrid immunoglobulinsGranulocyte colony-stimulating factorMyeloid leukemia
Owner:AMGEN INC +1
Inhibitors of histone demethylases
The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form (I)
Owner:GILEAD SCI INC
Inhibitors of histone demethylases
Compounds of the formIn which Q is selected from —CH═NR12, —W, —CH2NHR13, —CH═O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and / or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
Owner:GILEAD SCI INC
Small-molecular compound/combination for preventing, delaying or reversing aging of cells, tissues, organs and bodies, product thereof, and use of compound/combination and product
ActiveCN108300686AImprove quality controlIncrease production capacityCosmetic preparationsToilet preparationsHistone demethylationLife quality
The invention discloses a small-molecular compound / combination for preventing, delaying or reversing the aging of cells, tissues, organs and bodies, a product thereof, and a use of the compound / combination and the product. The small-molecular compound / combination includes at least one of a DNMT inhibitor, an HMT inhibitor, a histone demethylase inhibitor, a TGF-beta inhibitor, a WNT / beta-catenin agonist, a cAMP agonist, a lysine deacetylase inhibitor, an RAR agonist and an ROCK inhibitor. The small-molecular compound or the combination thereof is adopted to prevent, delay or reverse the agingof cells, tissues, organs and bodies and prolong the telomere length of the cells, and has the advantages of clear action target, clear, mature and stable composition, and accuracy in regulation of the anti-aging process; and the quality control and the large-scale production of the small-molecular compound are easy. The bodies or cells do not express dry genes in the action process, so the safetyis high; and the small-molecular compound and the combination thereof can be easily absorbed by the bodies, can prevent, delay and reverse the aging at the overall level of cells, tissues, organs andbodies, and is of great significance to delaying the process of human aging and improving the health state and the life quality.
Owner:云南美颜美龄生物科技有限公司
Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor
ActiveCN107176927AEnhanced inhibitory effectOrganic active ingredientsAntineoplastic agentsHistone demethylationStructural formula
The invention provides a histone demethylase LSD1 (lysine specific demethylase 1) inhibitor. The invention relates to piperazine-containing compounds and pharmacologically acceptable salts thereof and use of the piperazine-containing compounds and pharmacologically acceptable salts thereof as the LSD1 inhibitor; the general structural formula of the piperazine-containing compounds is described in the description. The invention belongs to the field of pharmaceutical chemistry. An in-vitro LSD1 activity inhibition test proves that the piperazine-containing compounds implemented by the invention have an obvious inhibiting effect for LSD1 activity, thus being used as active ingredients for preparing LSD1 inhibitor medicines.
Owner:福建金乐医药科技有限公司
Antiproliferative compounds
ActiveCN105611933AOrganic active ingredientsOrganic chemistryHistone demethylationMedicinal chemistry
Owner:GENENTECH INC +1
Pharmaceutical composition with synergistic anti-osteosarcoma effect and application thereof
ActiveCN108186643AGrowth inhibitionGood anti-tumor effectOrganic active ingredientsAntineoplastic agentsOsteosarcoma TumorHistone demethylation
Provided are a pharmaceutical composition with a synergistic anti-osteosarcoma effect and application thereof. The invention discloses the pharmaceutical composition containing a VEGFR2 selective inhibitor Apatinib and a histone demethylase inhibitor GSK-J4 and the application thereof. Apatinib and GSK-J4 are used in combination to achieve the synergistic anti-osteosarcoma effect, the osteosarcomacell growth can be obviously inhibited, and the pharmaceutical composition is used for treatment of tumors like osteosarcoma.
Owner:徐州维康生物科技有限公司
Application of histone demethylase KDM5C (lysine(K) demethylase 5C) in screening of drugs for treating the fatty liver and related diseases of the fatty liver
ActiveCN108220422ACompounds screening/testingMicrobiological testing/measurementPalmitic acidOleic Acid Triglyceride
The invention discloses an application of histone demethylase KDM5C (lysine(K) demethylase 5C) in screening of drugs for treating the fatty liver and related diseases of the fatty liver. A human normal hepatocyte L02 cell line, an L02 cell line with overexpressed histone demethylase KDM5C and an L02 cell line with KDM5C (CRISPR-Cas9) knockout are adopted as experimental subjects, and the functionof the gene KDM5C is studied by a fatty liver cell model induced by palmitic acid and oleic acid jointly. Studies show that the accumulation of lipid in L02 cells induced by PA and OA is significantlyincreased during overexpression of KDM5C; the accumulation of lipid in the L02 cells induced by PA and OA is significantly decreased when expression of KDM5C is decreased, that is, expression of thegene KDM5C can promote generation and development of the fatty liver and related diseases. Based on the function of KDM5C in deterioration of the fatty liver, a target for development of drugs for prevention, alleviation and / or treatment of the fatty liver and related diseases is provided.
Owner:武汉惠康达科技有限公司
Histone demethylase gene JMJ703 for regulating rice stem height, and applications thereof
InactiveCN103255152AImprove lodging resistanceGood plant typeOxidoreductasesFermentationHeterologousNicotiana tabacum
The invention discloses a histone demethylase gene JMJ703 for regulating a rice stem height, and applications thereof. According to the present invention, one of histone demethylases and gene JMJ703 thereof are selected through searching in a chromatin protein database, wherein the full-length cDNA accession number is AK121381, a gene ID number is 4338043, a prediction coding region comprises 3717 bp, and 1238 amino acids are coded; a RNA interference vector of the gene is transformed into rice through a RNA interference method, and results show that a stem height of the transgenic plant is shorter than a stem height of the wild type while a length of the leaf has no apparent change so as to improve a column shape of the rice; tobacco heterogenesis in vivo test results show that JMJ703 protein is demethylase of histone H3K4me1 / H3K4me2 / H3K4me3; and the JMJ703 is functional histone demethylase gene and can be provided for regulating a stem elongation process of the rice, wherein the stem of the rice expressed after gene inhibition becomes short and a characteristic of lodging resistance is provided while developments of leaves and other organs are normal so as to provide a selective plant type for breeding.
Owner:HUAZHONG AGRI UNIV
Applications of transcription factor CREB in JHDM2A gene expression regulation and pig lipid deposition reduction
InactiveCN104069482AReduce depositionImprove lean meat percentagePeptide/protein ingredientsMetabolism disorderBiotechnologyPhosphorylation
The invention relates to applications of a transcription factor CREB in JHDM2A gene expression regulation and pig lipid deposition reduction. By overexpression of CREB in pigs, or by improvement of the CREB phosphorylation level in pigs, or by promotion of combination of pig CBP protein and the phosphorylated CREB, JHDM2A gene expression in pigs is up-regulated, thus regulating lipid metabolism pathways from the epigenetics and reducing pig lipid deposition. Novel applications of the transcription factor CREB in the epigenetics are provided for the first time and the transcription factor CREB can be used for reducing pig lipid deposition, namely, expression of the histone demethylase JHDM2a is directly activated so that the histone demethylase JHDM2a can regulate the lipid metabolism pathways from the epigenetics, thus minifying lipid cells and increasing the meat factor. A novel candidate gene is provided for genetic breeding, meat quality improvement, and the like in the animal husbandry.
Owner:CHINA AGRI UNIV
Method Of Treatment
InactiveUS20120202875A1Inhibiting cytokine productionInhibit productionOrganic active ingredientsSugar derivativesDiseaseHistone demethylation
The present invention relates to methods for treatment or prevention of autoimmune and inflammatory diseases and conditions by inhibiting or modifying histone demethylation. In a further aspect the invention relates to a method for identifying agents useful in said methods of treatment. The invention particularly describes the role of certain histone demethylase enzymes in these diseases and conditions and their use as therapeutic and screening targets.
Owner:GLAXO GROUP LTD
Target regulation system for dedifferentiation of somatic cells, kit and application of kit
ActiveCN108060123AImprove production efficiencyClearly targetedSkeletal/connective tissue cellsCell culture active agentsHistone demethylationQuality control
The invention discloses a target regulation system for dedifferentiation of somatic cells, a kit and an application of the kit. The target regulation system regulates the somatic cells: inhibition ofPKC activity, inhibition of DNMT activity and / or inhibition of HMT activity and / or inhibition of the activity of histone demethylase; corresponding regulation key targets include PKC, DNMT and / or HMTand / or histone demethylase; the somatic cells are differentiated cells. The target regulation system provided by the invention can promote the efficiency of adopting small molecules to induce the somatic cells to transdifferentiate into different types of functional target cells, and has the advantages of clear targets, clear ingredients, maturity and stability, and easy quality control and large-scale production.
Owner:YUNNAN JICI INSITUTE FOR REGENERATIVE MEDICINE CO LTD
Method of preventing or treating viral infection
Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I):wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.
Owner:UNITED STATES OF AMERICA
Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
Substituted (E)-N-(1-phenylethylidene)benzohydrazide analogs or (3-(5-chloro-2-hydroxyphenyl)-4-METHYL-1 H-pyrazol-1-YL)(3- (morpholinosulfonyl)phenyl)methanone, derivatives thereof, and related compounds are useful as inhibitors of lysine-specific histone demethylase, including LSD1. Synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the LSD1 (lysine-specific demethylase). A pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof, and one or more of: (a) at least one agent known to increase histone demethylase activity; (b) at least one agent known to decrease histone demethylase activity; (c) at least one agent known to treat a disorder of uncontrolled cellular proliferation; (d) at least one agent known to treat a neurodegenerative disorder; (e) instructions for treating a neurodegenerative disorder; or (f) instructions for treating a disorder associated with uncontrolled cellular proliferation.
Owner:UNIV OF UTAH RES FOUND
5-benzylidene-2-phenyl thiazolone compound as well as preparation and application thereof
ActiveCN108689960ASimple manufacturing methodStrong antiproliferative activityOrganic active ingredientsOrganic chemistryDiseaseHistone demethylation
The invention relates to a 5-benzylidene-2-phenyl thiazolone compound as well as preparation and application thereof. In particular, the compound provided by the invention has a structure shown as a general formula (I), wherein the definitions of each group and substituent are described in the description. The invention further discloses a preparation method of the compound and application of thecompound to the prevention and / or treatment of cancer-related diseases. The compound provided by the invention has superior inhibitory activity on protein-arginine methyltransferases 1 (PRMT1), protein-arginine methyltransferases 5 (PRMT5) and histone demethylase LSD1, and can induce tumor cell apoptosis and retard tumor cells at a G1 stage, so that the compound can be used for preparing a seriesof medicaments for treating diseases related to abnormal activities of the PRMT1, the PRMT5 and the histone demethylase LSD1. The general formula (I) is shown in the description.
Owner:UNIV OF JINAN
Inhibitors of kinase networks and uses thereof
ActiveCN110662536AOrganic chemistry methodsHeterocyclic compound active ingredientsDiseasePharmaceutical drug
The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and / or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.
Owner:PURDUE RES FOUND INC
Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
![Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/7e9e923e-85d7-42c2-999b-ba167488c3e7/US09505767-20161129-C00001.png "Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors")
![Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/7e9e923e-85d7-42c2-999b-ba167488c3e7/US09505767-20161129-C00002.png "Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors")
![Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/7e9e923e-85d7-42c2-999b-ba167488c3e7/US09505767-20161129-C00003.png "Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors")
Owner:GENENTECH INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com